The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC

Introduction: Acquired MET gene amplification, MET exon 14 skip mutations, or MET fusions can emerge as resistance mechanisms to tyrosine kinase inhibitors (TKIs) in patients with lung cancer. The efficacy and safety of combining MET TKIs (such as crizotinib, capmatinib, or tepotinib) with parent TK...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Tejas Patil, MD, Alyse Staley, MS, Yunan Nie, MD, Mandy Sakamoto, MD, Margaret Stalker, MD, James M. Jurica, MD, MBA, Kenna Koehler, BA, Amanda Cass, PharmD, Halle Kuykendall, BA, Emily Schmitt, MS, Emma Filar, BA, Evelina Reventaite, MS, Kurt D. Davies, PhD, Hala Nijmeh, PhD, Mary Haag, PhD, Benjamin A. Yoder, PharmD, Paul A. Bunn, MD, Erin L. Schenk, MD, PhD, Dara L. Aisner, MD, PhD, Wade T. Iams, MD, Melina E. Marmarelis, MD, D. Ross Camidge, MD, PhD
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2024-02-01
Serie:	JTO Clinical and Research Reports
Ämnen:	NSCLC Tyrosine kinase inhibitor Acquired resistance MET amplification MET exon 14 skipping
Länkar:	http://www.sciencedirect.com/science/article/pii/S2666364324000079
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!